Cyclopentane-based modulators of STING (stimulator of interferon genes)

Patent metadata

Field	Value
Publication number	US-10968242-B2
Application number	US-201916702738-A
Country	US
Kind code	B2
Filing date	Dec 4, 2019
Priority date	Mar 15, 2018
Publication date	Apr 6, 2021
Grant date	Apr 6, 2021

Abstract

Compounds of the general formula (I):

or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

First claim

We claim:

1. A method of treating breast cancer in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the compound:

or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein said compound or salt is a component of an antibody-drug conjugate.

3. The method of claim 1 , wherein said compound or salt is a component of a particle-based delivery system.

4. The method of claim 1 , wherein the compound is

5. The method of claim 1 , wherein the compound is a pharmaceutically acceptable salt of

6. The method of claim 1 , wherein the compound is a single diastereoisomer of the compound

or a pharmaceutically acceptable salt thereof.

Assignees

• Pfizer

Inventors

• Wythes Martin James
• Mcalpine Indrawan James
• Patman Ryan
• Rui Eugene Yuanjin
• Maderna Andreas
• Jalaie Mehran
• Gajiwala Ketan S

Classifications

• C07H19/213 Primary

  containing cyclic phosphate · CPC title

• C07F9/65744 Primary

  condensed with carbocyclic or heterocyclic rings or ring systems · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/7042

  Compounds having saccharide radicals and heterocyclic rings · CPC title

• C07H19/23 Primary

  Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22 · CPC title